The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.
 
Shouyong Liu
No Relationships to Disclose
 
He Miao
No Relationships to Disclose
 
Song Xue
No Relationships to Disclose
 
Feng Xu
No Relationships to Disclose
 
Zhenyu Xu
No Relationships to Disclose
 
Dian Fu
No Relationships to Disclose
 
Haowei He
No Relationships to Disclose
 
Wenquan Zhou
No Relationships to Disclose
 
Jingping Ge
No Relationships to Disclose
 
Le Qu
No Relationships to Disclose